首页> 美国卫生研究院文献>BMC Endocrine Disorders >Similar immunogenicity profiles between the proposed biosimilar MYL-1501D and reference insulin glargine in patients with diabetes mellitus: the phase 3 INSTRIDE 1 and INSTRIDE 2 studies

【2h】

Similar immunogenicity profiles between the proposed biosimilar MYL-1501D and reference insulin glargine in patients with diabetes mellitus: the phase 3 INSTRIDE 1 and INSTRIDE 2 studies

机译：在糖尿病患者中拟议的生物仿生MyL-1501D和参考胰岛素狼科之间的类似免疫原性谱：第3阶段1和Instride 2研究

代理获取

本网站仅为用户提供外文OA文献查询和代理获取服务，本网站没有原文。下单后我们将采用程序或人工为您竭诚获取高质量的原文，但由于OA文献来源多样且变更频繁，仍可能出现获取不到、文献不完整或与标题不符等情况，如果获取不到我们将提供退款服务。请知悉。

页面导航

摘要
著录项
相似文献
相关主题

摘要

The online version contains supplementary material available at 10.1186/s12902-021-00797-4.

机译：在线版本包含10.1186 / S12902-021-00797-4的补充材料。

著录项

期刊名称 BMC Endocrine Disorders
作者
Bin Sun; Nilanjan Sengupta; Anita Rao; Charles Donnelly; Vinit Waichale; Arnab Sinha Roy; Shilpa Ramaswamy; Divya Pathak; Ronald R. Bowsher; Yaron Raiter; Patrick Aubonnet; Abhijit Barve;
展开▼
作者单位

展开▼
年(卷),期 2021(-1),-1
年度 2021
页码 -1
总页数 10
原文格式 PDF
正文语种
中图分类基础医学;
关键词

机译：BioSimilar;糖尿病;免疫原性;胰岛素Glargine;MyL-1501D;

相似文献

外文文献
中文文献
专利

1. Similar immunogenicity profiles between the proposed biosimilar MYL-1501D and reference insulin glargine in patients with diabetes mellitus: the phase 3 INSTRIDE 1 and INSTRIDE 2 studies [J] . Sun Bin, Sengupta Nilanjan, Rao Anita, BMC Endocrine Disorders . 2021,第1期

机译：在糖尿病患者中，拟议的生物仿生MyL-1501D和参考胰岛素狼科之间的类似免疫原性分布：第3阶段1和Instride 2研究
2. Efficacy and safety of MYL-1501D versus insulin glargine in patients with type 2 diabetes after 24 weeks: Results of the phase III INSTRIDE 2 study [J] . Blevins Thomas C., Barve Abhijit, Sun Bin, Diabetes, obesity & metabolism . 2019,第1期

机译：24周后2型糖尿病患者MyL-1501D与胰岛素冰壶的疗效和安全性：III阶段研究结果2研究
3. Efficacy and safety of MYL‐1501D vs insulin glargine in patients with type 1 diabetes after 52?weeks: Results of the INSTRIDE 1 phase III study [J] . Blevins Thomas C., Barve Abhijit, Sun Bin, Diabetes, obesity & metabolism . 2018,第8期

机译：MyL-1501D患者在52型糖尿病患者中的疗效和安全性的疗效和安全性，52型糖尿病患者：Thee：Instride 1期III研究的结果
4. Switching to insulin glargine 300 U/mL from other basal insulin analogues provides less 24-hour glucose variability in hospitalized patients with type 1 diabetes [C] . V.V. Klimontov, E.A. Koroleva, O.N. Fazullina International Multiconference Bioinformatics of Genome Regulation and StructureSystems Biology . 2018

机译：从其他基础胰岛素类似物转换为甘精胰岛素300 U / mL可使住院的1型糖尿病患者的24小时葡萄糖变异性降低
5. Modeling of the insulin pathway in insulin therapy to improve normoglycemic control of patients wtih type 1 diabetes mellitus [D] . Chan, Alice 2011

机译：胰岛素治疗中胰岛素途径的建模以改善1型糖尿病患者的正常血糖控制
6. Immunogenicity and Efficacy of Insulin Glargine Biosimilar Ezelin versus Originator Insulin Glargine in Patients with Type 2 Diabetes [O] . Tri Juli Edi Tarigan, Adisti Dwijayanti, Susie Setyowati, 2021

机译：2型糖尿病患者胰岛素狼生物纤维蛋白生物蛋白胰蛋白酶对胰岛素胰岛素狼犬的免疫原性和疗效
7. FRI0088 SAFETY, IMMUNOGENICITY AND EFFICACY OF THE PROPOSED BIOSIMILAR MSB11022 (MODIFIED FORMULATION) COMPARED WITH ADALIMUMAB REFERENCE PRODUCT IN PATIENTS WITH MODERATELY TO SEVERELY ACTIVE RHEUMATOID ARTHRITIS: AURIEL-RA, A RANDOMISED, DOUBLE-BLIND, PHASE III STUDY [O] . Christopher Edwards, Veronica Chyrok, Joëlle Monnet, 2019

机译：与患者中适度至严重活性类风湿性关节炎的患者的Adalimalab参考产物相比，Fri0088的安全性，免疫原性和疗效与患者的安全性，免疫原性和疗效相比：Auriel-Ra，随机，双盲，第三期研究

Similar immunogenicity profiles between the proposed biosimilar MYL-1501D and reference insulin glargine in patients with diabetes mellitus: the phase 3 INSTRIDE 1 and INSTRIDE 2 studies

摘要

著录项

相似文献

相关主题

期刊订阅